Oxford, UK-based biotech Immunocore, the soluble TCR company developing first-in-class biologics that have the potential to transform patient lives, has announced that Dr Eliot Forster has stepped down as chief executive. 12 February 2018
Following the departure of Christophe Bourdon in December, US drugmaker Alexion Pharmaceuticals has named his replacement in the role of senior vice president and head of Europe/Middle East/Africa/Canada (EMEAC). 30 January 2018
Belgian biotech firm Ablynx today announced the appointment of Robert Friesen as chief scientific officer (CSO), effective March 1, 2018. 24 January 2018
Dr Peter Fellner, who has served as chairman of Belgian biotech firm Ablynx since 2013, has decided to resign from the board with immediate effect. 9 January 2018
US biotech Neurocrine Biosciences has named an experienced Eli Lilly executive its new chief medical officer after Christopher O'Brien announced that he would be retiring. 8 January 2018
US biotech firm Array BioPharma has launched a new subsidiary to develop drugs using its ARRY-797 drug program, according to a filing with the US Securities and Exchange Commission (SEC). 30 December 2017
Clinical-stage US biotech Provectus Biopharmaceuticals has reached a settlement with the US Securities and Exchange Commission (SEC) in connection with investigations relating to two former executives and the company. 13 December 2017
French biotech company Cellectis has appointed Professor Stéphane Depil to the role of senior vice president R&D and chief medical officer. 5 December 2017
Alligator Bioscience today announced the expansion of its management team with the appointment of Charlotte Russell as chief medical officer and Peter Ellmark as vice president discovery. 4 December 2017
The Supervisory Board of Selvita has appointed Edyta Jaworska to the position of a management board member, responsible for the development of its integrated drug discovery services. 30 November 2017
Canadian clinical-stage immuno-oncology (I-O) company Turnstone Biologics has named Mike Burgess as president of research and development (R&D). 16 November 2017
Belgian biotech firm ThromboGenics, which is focussed on developing novel medicines for back of the eye diseases and focused on diabetic eye disease, today announced it has strengthened its senior leadership team, attracting former executives from Allergan and Novartis. 8 November 2017
Chirfi Guindo has been appointed executive vice president and head of global marketing, market access and customer innovation at US biotech major Biogen. 3 November 2017
Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy treatments that are changing cancer care, has announced several key leadership appointments to further the company’s continued growth and expansion. 27 October 2017
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024